Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers

NEUROBIOLOGY OF AGING

卷:100

Article

Ouk, Michael^1,2  Wu, Che-Yuan^1,2  Rabin, Jennifer S.^2,3,4  Edwards, Jodi D.^5,6,7  Ramirez, Joel^2,8  Masellis, Mario^2,4  Swartz, Richard H.^2,4,8  Herrmann, Nathan^2,9  Lanctot, Krista L.^1,2,9,10  Black, Sandra E.^2,4,8,10  Swardfager, Walter^1,2,8,10 

[1] Univ Toronto, Dept Pharmacol & Toxicol, Room 4207,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada

[2] Sunnybrook Res Inst, Hurvitz Brain Sci Program, Toronto, ON, Canada

[3] Sunnybrook Res Inst, Harquail Ctr Neuromodulat, Toronto, ON, Canada

[4] Univ Toronto, Dept Med Neurol, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[5] Univ Ottawa, Inst Heart, Ottawa, ON, Canada

[6] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada

[7] ICES, Ottawa, ON, Canada

[8] Canadian Partnership Stroke Recovery, Toronto, ON, Canada

[9] Univ Toronto, Dept Psychiat, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[10] Univ Hlth Network, KITE Toronto Rehabil Inst, Toronto, ON, Canada

关键词: Alzheimer's disease;    Amyloid;    Hypertension;    Dementia;    Biomarkers;   

DOI  :  10.1016/j.neurobiolaging.2020.12.011

来源: Elsevier

【 摘 要 】

Some studies suggest that angiotensin II type 1 receptor blockers (ARBs) may protect against memory decline more than angiotensin-converting enzyme inhibitors (ACE-Is), but few have examined possible mechanisms. We assessed longitudinal differences between ARB versus ACE-I users in global and sub-regional amyloid-beta accumulation by F-18-florbetapir. In cognitively normal older adults (n= 142), propensity-weighted linear mixed-effects models showed that ARB versus ACE-I use was associated with slower amyloid-beta accumulation in the cortex, and specifically in the caudal anterior cingulate and pre-cuneus, and in the precentral and postcentral gyri. In amyloid-positive participants with Alzheimer's disease dementia or mild cognitive impairment (n = 169), ARB versus ACE-I use was not associated with different rates of amyloid-beta accumulation. Apolipoprotein E epsilon 4 carrier status explained some heterogeneity in the different rates of amyloid-beta accumulation between users of ARBs versus ACE-Is in the study. Replicative studies and clinical trials are warranted to confirm potential benefits of ARBs on rates of amyloid-beta accumulation in the contexts of Alzheimer's disease prevention and treatment. (C) 2020 Elsevier Inc. All rights reserved.

【 授权许可】

Free